Vascular & Endovascular Highlights: Startup behind embolization tech finds a new home | 'Staggering' CVD data

News You Need to Know Today

Tuesday, August 16, 2022

Editor's Choice: Vascular & Endovascular

Boston Scientific acquires startup behind new FDA-cleared embolization technology

The new hydrogel material was designed to immediately conform to the patient's body and create a barrier.

Boston Scientific acquires startup behind new FDA-cleared embolization technology

The new hydrogel material was designed to immediately conform to the patient's body and create a barrier.

Programmable RNA-DNA anticoagulant fibers may provide a better balance between blood clots and bleeding risks

“We can learn from nature, but we have built something that has never been introduced before,” one researcher said.

Programmable RNA-DNA anticoagulant fibers may provide a better balance between blood clots and bleeding risks

“We can learn from nature, but we have built something that has never been introduced before,” one researcher said.

Cardiologists sound the alarm as ‘staggering’ new data suggest CVD rates in the U.S. will rise dramatically

New data from the CDC and U.S. Census Bureau show just how bad CVD rates could get in the next few decades. Specialists agree that a lot of work is needed to help keep these estimates from becoming a reality.

Cardiologists sound the alarm as ‘staggering’ new data suggest CVD rates in the U.S. will rise dramatically

Cardiovascular devices lead FDA Breakthrough Device Designation program

The FDA said cardiovascular devices make up the largest number of technologies accepted into the Breakthrough Devices Program, and several are on the list of the first 50 in the program to gain market clearance.

The Harmony pulmonary valve was among the devices involved with the FDA Breakthrough Device Designation program that gained more rapid market clearance. The FDA graph shows cardiovascular devices leading the types of devices involved in the program.

Cardiovascular devices lead FDA Breakthrough Device Designation program

Peripheral artery disease patients benefit if they push through discomfort when walking

Researchers said they were surprised to learn that "no pain, no gain" was so accurate for this patient population.

Researchers said they were surprised to learn that "no pain, no gain" was so accurate for patients with peripheral artery disease (PAD). A news study found patients should push past the pain because it improves outcomes.

Peripheral artery disease patients benefit if they push through discomfort when walking

Researchers said they were surprised to learn that "no pain, no gain" was so accurate for this patient population.

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us | Unsubscribe from all | Privacy Policy

© Innovate Healthcare, a TriMed Media brand

Editor's Choice: Vascular & Endovascular

Recent Newsletters